Chemical Property of Valdecoxib
Chemical Property:
- Appearance/Colour:White crystalline powder
- Vapor Pressure:2.03E-09mmHg at 25°C
- Melting Point:162-164 °C
- Refractive Index:1.608
- Boiling Point:481.191 °C at 760 mmHg
- PKA:9.83±0.10(Predicted)
- Flash Point:244.815 °C
- PSA：94.57000
- Density:1.303 g/cm3
- LogP:4.74550
- Storage Temp.:Store at RT
- Solubility.:DMSO: >25mg/mL
- XLogP3:2.6
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:3
- Exact Mass:314.07251349
- Heavy Atom Count:22
- Complexity:462
- Purity/Quality:
-
99% *data from raw suppliers
Valdecoxib *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xn,N
- Hazard Codes:Xn,N
- Statements:
63-48/22-51/53
- Safety Statements:
36/37-61
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
- Recent ClinicalTrials:A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
- Recent EU Clinical Trials:RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF THE EFFICACY, TOLERABILITY AND SAFETY OF VALDECOXIB (BEXTRA?)10 MG OD VS. DICLOFENAC SODIUM 50 MG TDS FOR 6 WEEKS IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE.
-
Description
Valdecoxib is a second-generation COX-2 inhibitor, developed as a follow-up to celecoxib for the oral once-daily treatment of osteoarthritis, adult rheumatoid arthritis and menstrual pain. Valdecoxib is approximately 28,000-fold more selective against human recombinant COX-2 than human recombinant COX-1. In an ex viva human whole blood assay, the I&O values against COX-2 and COX-1 were respectively 0.89 PM and 25.4 FM. In animal models, valdecoxib possesses excellent oral activity as an antiinflammatory. In rats, valdecoxib potently inhibited carrageenan footpad edema and adjuvant-induced arthritis.
-
Uses
Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in animal models. It is a potent and selective inhibitor of prostaglandin synthesis primarily through inhibition of COX-2. Valdecoxib is used to relieve some symptoms caused by arthritis (rheumatism), such as inflammation, swelling, stiffness, and joint pain.
-
Clinical Use
Valdecoxib is approved for the relief of the signs and symptoms of osteoarthritis and adult rheumatoid arthritis and
for the treatment of primary dysmenorrhea. Valdecoxib is contraindicated for the treatment of postoperative pain
immediately following coronary artery bypass graft surgery.
